Shigellosis - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Shigellosis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Shigellosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Shigellosis: Overview
Shigellosis is a bacterial infection caused by a group of bacteria called Shigella. It affects the digestive system. Shigella is very contagious and spread through contaminated water and food or via contact with contaminated feces. The bacteria release toxins that irritate the intestines. The primary symptom of shigellosis is diarrhea. Shigella are usually found in the feces of infected people. The bacteria are spread when someone comes into contact with the stool of an infected person, or with something that has been contaminated with the stool or the bacteria. Contaminated food and water are also a common cause of shigellosis. The main goal of treatment is preventing dehydration for most cases of shigellosis. Treatment usually includes antibiotics to eliminate the bacteria from the digestive tract.
“Shigellosis- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Shigellosis pipeline landscape is provided which includes the disease overview and Shigellosis treatment guidelines. The assessment part of the report embraces, in depth Shigellosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Shigellosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Shigellosis R&D. The therapies under development are focused on novel approaches to treat/improve Shigellosis.
Shigellosis Emerging Drugs Chapters
This segment of the Shigellosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Shigellosis Emerging Drugs
Shigella 4v: GlycoVaxyn
It is a biconjugate (Tetravalent) vaccine. Currently, in phase II of clinical trials for the treatment of shigella infection.
SF2a-TT15: Institut Pasteur
A synthetic carbohydrate-based Shigella flexneri 2a vaccine candidate.
Further product details are provided in the report……..
Shigellosis: Therapeutic Assessment
This segment of the report provides insights about the different Shigellosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Shigellosis
There are approx. 5+ key companies which are developing the therapies for Shigellosis. The companies which have their Shigellosis drug candidates in the mid to advanced stage, i.e. Phase II include, GlycoVaxyn and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Shigellosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Shigellosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Shigellosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Shigellosis drugs.
Shigellosis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Shigellosis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Shigellosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Shigellosis: Overview
Shigellosis is a bacterial infection caused by a group of bacteria called Shigella. It affects the digestive system. Shigella is very contagious and spread through contaminated water and food or via contact with contaminated feces. The bacteria release toxins that irritate the intestines. The primary symptom of shigellosis is diarrhea. Shigella are usually found in the feces of infected people. The bacteria are spread when someone comes into contact with the stool of an infected person, or with something that has been contaminated with the stool or the bacteria. Contaminated food and water are also a common cause of shigellosis. The main goal of treatment is preventing dehydration for most cases of shigellosis. Treatment usually includes antibiotics to eliminate the bacteria from the digestive tract.
“Shigellosis- Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Shigellosis pipeline landscape is provided which includes the disease overview and Shigellosis treatment guidelines. The assessment part of the report embraces, in depth Shigellosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Shigellosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Shigellosis R&D. The therapies under development are focused on novel approaches to treat/improve Shigellosis.
Shigellosis Emerging Drugs Chapters
This segment of the Shigellosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Shigellosis Emerging Drugs
Shigella 4v: GlycoVaxyn
It is a biconjugate (Tetravalent) vaccine. Currently, in phase II of clinical trials for the treatment of shigella infection.
SF2a-TT15: Institut Pasteur
A synthetic carbohydrate-based Shigella flexneri 2a vaccine candidate.
Further product details are provided in the report……..
Shigellosis: Therapeutic Assessment
This segment of the report provides insights about the different Shigellosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Shigellosis
There are approx. 5+ key companies which are developing the therapies for Shigellosis. The companies which have their Shigellosis drug candidates in the mid to advanced stage, i.e. Phase II include, GlycoVaxyn and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase II/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Shigellosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Parenteral
- Intramuscular
- Molecule Type
- Small molecules
- Peptides
- Polymer
- Gene Therapy
- Monoclonal antibodies
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Shigellosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Shigellosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Shigellosis drugs.
Shigellosis Report Insights
- Shigellosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Shigellosis drugs?
- How many Shigellosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Shigellosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Shigellosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Shigellosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- GlycoVaxyn
- Institut Pasteur
- GlaxoSmithKline
- SF2a-TT15
- Shigella 4v
- 1790GAHB vaccine
Introduction
Executive Summary
Shigellosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Shigellosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Shigellosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Shigellosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Shigella 4v: GlycoVaxyn
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Shigellosis Key Companies
Shigellosis Key Products
Shigellosis- Unmet Needs
Shigellosis- Market Drivers and Barriers
Shigellosis- Future Perspectives and Conclusion
Shigellosis Analyst Views
Shigellosis Key Companies
Appendix
Executive Summary
Shigellosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Shigellosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Shigellosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Shigellosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Shigella 4v: GlycoVaxyn
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Shigellosis Key Companies
Shigellosis Key Products
Shigellosis- Unmet Needs
Shigellosis- Market Drivers and Barriers
Shigellosis- Future Perspectives and Conclusion
Shigellosis Analyst Views
Shigellosis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Shigellosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Shigellosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Shigellosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Shigellosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
